Apricus Biosciences, Inc.
("Apricus Bio" or the "Company") APRI (www.apricusbio.com), today
announced that Germany's Federal Institute for Drugs and Medical Devices
(BfArM) has granted national phase approval to Vitaros^®, indicated for the
treatment of patients with erectile dysfunction ("ED"). The Company has now
received a total of five national phase approvals for Vitaros^®, including
Germany, Ireland, the Netherlands, Sweden and the United Kingdom ("UK").
"National phase approval of Vitaros^® in Germany, one of the largest ED
markets in Europe, is another important milestone for the Company," said
Richard Pascoe, Chief Executive Officer of Apricus Bio. "We look forward to
working with Sandoz, our commercialization partner in Germany, to move
Vitaros^® toward a successful launch in this key territory. Our regulatory
efforts, along with actions taken by our existing European partners, continue
to be on track to obtain the remaining five of ten European approvals from the
fourth quarter of 2013 through the first quarter of 2014."
In June 2013, Apricus Bio announced that its marketing application for
Vitaros^® was approved through the European Decentralized Procedure
("DCP"). Under the DCP, Apricus Bio filed its application for marketing
approval designating Netherlands as the Reference Member State ("RMS") on
behalf of nine other European Concerned Member States ("CMS") participating in
the procedure. The Company continues to work independently, as well as with
its commercialization partners, to obtain country-by-country national phase
approvals in the remaining CMS territories including France, Italy, Spain,
Belgium and Luxembourg. Once the national phase approvals are secured on a
country-by-country basis, marketing of Vitaros^® can then be initiated in each
country by Apricus Bio's commercialization partners.
Once launched, Vitaros^® will become the first new and novel ED product in
nearly a decade, and with its unique product profile that addresses a large
number of patients who cannot or do not respond well to the existing
therapies, or who are intolerant to the systematic effects of PDE5 inhibitors,
it is well-positioned for commercial success. In Europe alone, the existing ED
products generated over $1 billion in sales in 2012. Apricus Bio believes that
a significant portion of the market remains untreated or under-treated, which
represents a substantial commercial opportunity for Vitaros^®.
Vitaros^® is currently partnered in key markets, including with Takeda in the
UK, Sandoz in Germany, Bracco in Italy and Abbott in Canada. Apricus Bio has
launched a comprehensive partnering process with the goal of licensing
Vitaros^® in the remaining un-partnered territories in Europe, Latin America
and North Africa. Apricus Bio has received and reviewed multiple bids for the
available territories and has narrowed the number of potential partners to a
select group with which it will negotiate terms. Moreover, the Company
remains on track to complete this process in the fourth quarter of this year.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in